{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-006269","form_type":"8-K","ticker":null,"cik":"0000846475","company_name":"ZYNEX INC","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.131570+00:00","generated_at":"2026-06-03T05:09:23.128174+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zynex Q1 revenue up 10% to $46.5M; net income near zero; orders up 23% YoY","bullets":["Q1 revenue $46.5M (+10% YoY); missed $47.5M guidance due to cyber incident delaying insurer payments; full-year $227M guide reaffirmed.","Net income $10,000 ($0.00 diluted EPS); adjusted EBITDA $1.7M; orders hit eighth consecutive quarterly record, up 23% YoY.","Repurchased $13.4M of stock in Q1; $78.5M over past 24 months.","FDA clearance for next-gen M-Wave NMES device; launched Zynex Pro Hybrid LSO and DynaComp Cold Compression therapy products.","Q2 guidance: revenue at least $52M, diluted EPS at least $0.08; FY 2024: revenue at least $227M, diluted EPS at least $0.50."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-006269","json":"https://secwatch.observer/filing/0001558370-24-006269.json","markdown":"https://secwatch.observer/filing/0001558370-24-006269.md","text":"https://secwatch.observer/filing/0001558370-24-006269.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/846475/000155837024006269/0001558370-24-006269-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/846475/000155837024006269/zyxi-20240430x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:09:23.128174+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f3727b475253441e59fcb1ad333c0177d97e296d","claim":"ZYNEX INC reported the first quarter of 2024 results: revenue $46.5 million, net income $10,000, EPS $0.00. Guidance reaffirmed.","evidence_excerpt":"Zynex Reports First Quarter 2024 Financial Results Q1 2024 Revenue Increased 10% to $46.5 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/846475/000155837024006269/0001558370-24-006269-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2024"},{"label":"Revenue","value":"$46.5 million"},{"label":"Net income","value":"$10,000"},{"label":"EPS","value":"$0.00"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}